メシル酸イマチニブによる皮膚症状と肝機能障害を脱感作療法によって克服しえた慢性骨髄性白血病の1例

概要

論文の詳細を見る
Imatinib mesilate (Glivec^[○!R]), a selective inhibitor of Bcr-Abl tyrosine kinase, has shown significant efficacy in chronicphase chronic myeloid leukemia (CML) with minimal toxicity. However, some patients have to discontinue Imatinib due to adverse reactions. A 67-year-old Japanese man with CML was started on 400mg/day of Imatinib. On day 13 of treatment, he developed a generalized skin rash and was treated with an oral steroid. As the skin rash was aggravated and serum liver transaminase levels increased, Imatinib was discontinued on day 20. Three weeks later, the skin rash had abated and serum liver transaminase levels had returned to the normal range. Based on the pharmacist's recommendation, desensitization to Imatinib was attempted. To do this, its administration was restarted at a dose of 1mg/day and then the dose was gradually increased at 2-day intervals-to 2, 5, 10, 25, 50 and then 100mg/day, taking adequate care while doing so. Subsequently, the patient was able to take 400mg/day of Imatinib with no recurrence of the rash or liver dysfunction. These findings suggest that desensitization therapy should be attempted for patients exhibiting adverse reactions to Imatinib.
日本医療薬学会の論文
2007-01-10